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Beta cell mass and function are decreased to varying degrees in diabetes. Islet cell replacement or regenerative therapy may 
offer great therapeutic promise to people with diabetes. In addition to primary pancreatic  cells, recent studies on regeneration 
of functional insulin producing cells (IPCs) revealed that several alternative cell sources, including embryonic stem cells, in-
duced pluripotent stem cells and adult stem cells, can generate IPCs by differentiation, reprogramming, and trans-differentiation. 
In this review, we discuss stem cells as a potential alternative cell source for the treatment of diabetes. 
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Diabetes mellitus is a glucose metabolism disorder that is 
caused by insulin secretion deficiency or dysfunction, and is 
characterized by the elevation of blood glucose. At present, 
there are approximately 346 million adult diabetic patients 
worldwide. By 2030, the number of diabetic patients is ex-
pected to reach 4 billion [1]. Based on etiology, diabetes is 
divided into three categories. (i) Type I diabetes (T1DM) is 
an autoimmune endocrine disease mediated by T cells. It is 
generally believed that immune dysfunction is the main 
pathogenesis of T1DM, and that T1DM has a strong genetic 
predisposition. When the susceptible population is exposed 
to environmental factors, T cells alter their function and 
secrete large amounts of interleukin-2. Cytokines such as 
-interferon trigger an inflammatory response in the pancre-
atic islets, which damages  cells, resulting in dysfunction 
and insulin secretion deficiency [2], thus triggering T1DM 
[2]. (ii) Type II diabetes mellitus (T2DM) consists of hy-
perinsulinemia and insulin resistance. Under normal condi-
tions, insulin reduces blood glucose levels via activation of 
insulin signaling pathways in the muscle, liver and adipose 
tissues. However, in patients with T2DM, the insulin sensi-
tivity is decreased in such peripheral tissues. Persistent high 
blood glucose levels and stimulation of  cells will damage 
 cells, leading to serious defects of  cell function and im-
pairment of insulin secretion. Insulin resistance and the in-
cidence of T2DM may result from heredity, obesity, poor 
lifestyle and other factors. However, its molecular mecha-
nism remains unknown [3]. Although the pathogenesis of 
T1DM differs from that of T2DM, the two exhibit similar 
pathological changes including glucose intolerance, hyper-
glycemia, hyperlipidemia, and related organ complications. 
(iii) Gestational diabetes mellitus is a special type of diabe-
tes mellitus. Pregnancy leads to physiological insulin re-
sistance, increased hormone secretion under various anti-       
insulin effects, and corresponding increased insulin re-
quirements with peaks in the second trimester of pregnancy. 
Because of the limitation of insulin secretion, if compensa-
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tory physiological changes are not maintained, pregnant 
women may develop hyperinsulinemia or hyperglycemia. 
Following childbirth, blood glucose levels return to normal. 
Gestational diabetes mellitus significantly increases neona-
tal and intrauterine fetal mortality, and affects the health of 
both the mother and baby. 
Although modern medicine has made considerable pro-
gress in the treatment of diabetes, lifelong exogenous insulin 
therapy is still required for management of T1DM and T2DM, 
thereby increasing the occurrence of infection, ketoacidosis, 
hypoglycemia, chronic complications, as well as retinal, 
nervous, renal, cardiovascular and cerebrovascular illnesses 
[4]. Although pancreas and pancreatic islet transplantation 
have made remarkable progress in establishment of an en-
dogenous insulin secretion system [5,6], the current significant 
shortage of donor organs has hindered its extensive develop-
ment. Therefore, the development of stem cell transplantation 
may be the ideal choice for the treatment of T1DM. 
Stem cells are a type of cell with strong self-renewal abil-
ity and the potential for differentiation. In theory, pluripotent 
stem cells have the ability to differentiate into all cell types of 
the body. Therefore, they are an ideal cell source for regener-
ative medicine and tissue engineering. It has been found that 
stem cells are capable of replacing aging, damaged or dead 
cells in mature organs. Therefore, stem cells have been in-
creasingly used in the treatment of various end-stage re-
fractory diseases (e.g., myocardial infarction, severe burns, 
and degenerative diseases of the nervous system). This arti-
cle reviews the research progress made in recent years re-
garding stem cell-derived insulin-producing cells (IPCs) for 
the treatment of diabetes mellitus. 
1  Research status of stem cell replacement 
therapy for diabetes mellitus 
Since insulin was first discovered and isolated in 1920, ex-
ogenous insulin replacement has become the main treatment 
for the control of plasma glucose levels. Diabetes is caused 
by the loss of a specific cell function. In theory, pancreas 
transplantation may be used as a cell replacement therapy to 
compensate for the loss of  cell function. From 1966 to 
2008, a total of more than 30000 pancreas transplantations 
were performed [7]. Because pancreas transplantation is 
complex and accompanied by many postoperative complica-
tions, researchers have studied islet transplantation, and con-
firmed increased levels of serum C-peptide after transplanta-
tion. Islet transplantation is a simple and minimally invasive 
process. In the Edmonton protocol of 2000, seven patients 
refrained from insulin therapy for an average of 11.9 months 
[8]. Although pancreatic and pancreatic islet transplantation 
has achieved positive therapeutic effects, the significant 
shortage of donor organs remains an issue.  
Even though pancreas transplantation and islet transplan-
tation are not the conventional treatment for diabetes melli-
tus, successful transplantation of  cells has resulted in a 
new breakthrough in stem cell therapy. With the potential of 
multiple differentiating and self-renewal, stem cells have 
demonstrated superiority in cell replacement therapy, as 
well as unique roles in developmental biology and other 
fields of study. Stem cell therapy has the following ad-
vantages for the treatment of diabetes mellitus. It is not lim-
ited by the donor source, and can provide a long-term 
source for functional  cells. Stem cell-derived islet cells 
can avoid allograft rejection, thereby reducing the necessity 
for immunosuppressive therapy. They are also capable of 
secreting a variety of cytokines and improving the local 
microenvironment of pancreatic lesions, thereby improving 
the prognosis. The stem cells used for  cell replacement 
include pancreatic stem cells, hepatic stem cells, mesen-
chymal stem cells (MSCs), embryonic stem cells (ESCs), 
and induced pluripotent stem cells (iPSCs). 
1.1  Pancreatic stem cells 
The islet contains four types of functional cells: glucagon-   
secreting  cells, insulin-secreting  cells, somatostatin-       
secreting  cells, and pp cells. Promoting the proliferation 
of existing  cells is the most direct and convenient source 
of new  cells. During postnatal development,  cells pro-
liferate in great numbers with physiological changes, such 
as pregnancy and obesity, suggesting that these cells are 
capable of self-renewal. Studies have shown that, after adult 
rats undergo resection of 90% of the pancreas, pancreatic 
tissues and  cells can regenerate efficiently [9]. However, 
it remains controversial whether new  cells are derived 
from the proliferation of existing  cells or the differentia-
tion of pancreatic stem cells. 
Wang [10] found that ligation of the pancreatic duct of 
rats results in the formation of a large number of new islets, 
which mainly consist of -like cells, and that the formation 
of new  cells cannot be completely attributed to the prolifer-
ation of existing  cells. The researchers therefore assumed 
that new  cells are derived from stem cells, which may 
originate from the differentiation and proliferation of pan-
creatic duct cells. Xu [11] found that neurogenin 3 (NGN3)-      
positive cells are present after pancreatic duct ligation, and 
under suitable conditions, these cells can differentiate into 
IPCs in vitro. Inada [12] also supported the theory that the 
pancreatic duct, acinus and islet are postnatally derived 
from pancreatic duct epithelial cells. Nevertheless, whether 
the pancreatic duct epithelium is the source of  cells re-
mains controversial. Furayama [13] performed several ex-
periments in vivo to stimulate pancreatic regeneration, and 
found no pancreatic progenitor cell-derived  cells using a 
lineage tracing method. During embryonic development, it 
is assumed that endocrine cells are derived from the pancre-
atic duct epithelial cells and separate from SRY-related high 
mobility group-box gene 9-positive progenitor cells, and 
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that  cells are sustained by self-renewal of existing  cells. 
Of course, the lineage tracing methods currently used have 
limitations. Because the labeling efficiency may be very 
low, most of the ductal cells are not labeled. Therefore, it is 
uncertain whether  cell progenitors are present among the 
ductal cells. 
Scientists have also discovered pluripotent cells in the 
pancreatic islets of humans and rats, which may be catego-
rized into various types of pancreatic endocrine cells. 
However, Bonner [14] believed that, to a certain degree, the 
processes of  cell growth and regeneration do not involve 
specific progenitor cells, but rather slow replication of ma-
ture  cells. Brennand [15] confirmed that  cells are ho-
mogenous cells that can sustain themselves through slow 
replication. So directly promoting the proliferation rate of β 
cell maybe the best way to obtain enough  cell for cell 
therapy. However, although it has been found that a large 
number of factors promote  cell proliferation through dif-
ferent mechanisms, such as glucose transporter protein 1 
and corticotropin-releasing factor receptor type 1 [16], the 
detailed mechanisms remain unclear. Elaborating the 
mechanism of  cell self-renewal is important to obtain new 
 cells from existing  cells. However, at present, many 
difficulties still remain for obtaining adequate numbers of 
new  cells from the existing  cells. Although the sources 
of pancreatic stem cells are controversial. Simon et al. [17] 
isolated pancreatic-duodenal homeobox 1 (PDX1)+/insulin+/     
glucose transporter isoform 2– cells from the pancreatic duct 
and pancreatic islet tissues of transgenic mice by lineage 
tracing and cell sorting. These cells formed spheres and 
expanded clonally in vitro, and could differentiate into var-
ious types of pancreatic cells. Transplantation of this cell 
population ameliorated diabetes in streptozocin (STZ)-     
treated mice. Thus, the authors defined this group of cells as 
pancreatic progenitor cells.  
Exocrine gland cells, the major cell type in the pancreas, 
are one of the alternative sources of  cells. PDX1 is a spe-
cific transcription factor of pancreatic progenitor cells and a 
gene with spontaneous induction and self-enhancing ex-
pression. Similar to endocrine cells, exocrine cells also 
originate from PDX1-positive pancreatic progenitor cells, 
and under suitable conditions, can be induced to possess the 
phenotypic characteristics of endocrine cells [18]. In 2008, 
Zhou [19] used three transcription factors, PDX1, NGN3 
and macrophage activating factor A, to convert pancreatic 
exocrine cells into -like cells. Although these cells are very 
different from intrinsic β cells in terms of size, shape and 
ultrastructure, they are capable of secreting insulin and alle-
viate the symptoms of hyperglycemia.  
1.2  Embryonic stem cells and induced pluripotent stem 
cells 
Early studies of ESCs mainly focused on mouse ESCs to 
avoid ethical controversies. Through in vitro differentiation, 
a small amount of pancreatic cells (1%–3%) can be ob-
tained [20]. However, although in vitro differentiation can 
generate pancreatic endocrine cells, it is not possible to pre-
cisely control the differentiation or determine whether the 
insulin in the cells is derived from synthesis or uptake from 
the induction medium [21]. It is generally accepted that the 
maintenance of  cell function depends on the microenvi-
ronment of the pancreatic islet, and especially on the inter-
action among ,  and  cells. Kahan [22] found that mouse 
ESCs can only maintain an optimal state of differentiation 
in the presence of islet cells, and particularly emphasized 
the importance of the microenvironment in the differentia-
tion of ESCs [23]. Based on this perspective, researchers 
have transplanted ESC-derived pancreatic endocrine pro-
genitor cells into mice to observe their maturation and ther-
apeutic effects. 
Brolen [21] used human ESCs to obtain pancreatic pro-
genitor cells. Although the cells expressing PDX1 were 
confirmed to be pancreatic progenitor cells, they were una-
ble to secrete insulin and showed no glucose reactivity. 
However, these cells continued to differentiate and mature 
after transplantation into a mouse, thereby possessing the 
abilities of insulin synthesis and processing. Together with 
similar results obtained by Kahan, this study showed that 
human ESCs are capable of responding to environmental 
signals in the body and differentiating into endocrine islet 
cells. These results also provide evidence for the relation-
ship between the mouse in vivo environment and human 
cells, suggesting that a conserved mechanism of islet de-
velopment exists in humans and mice.  
The findings of D’Amour [23] are an important milestone 
for the investigation of human ESC-derived IPCs. They first 
differentiated ESCs to IPCs in five stages: definitive endo-
derm, forgut, hindgut, pancreatic endoderm, and then endo-
crine cells. The steps of the differentiation protocol are 
based on the developmental biology of the pancreas. The 
insulin content of these cells is similar to that in human fetal 
islet cells. The cells are capable of secreting insulin under 
stimulation by potassium chloride and various other secret-
agogue agents, but unfortunately do not respond to glucose 
stimulation. Glucose-stimulated insulin secretion is an im-
portant indicator to evaluate the functional maturity of  
cells. The neonatal islet has normal functions at about 4 
weeks after birth, indicating that the endocrine cells ob-
tained by D’Amour were still at the immature islet stage. 
Because of the current lack of understanding of the mecha-
nism of functional islet maturation in vivo, an effective 
method to promote islet maturity in vitro has yet to be found. 
To verify the maturity and therapeutic effects of these cells 
[24], ESCs have been induced to pancreatic progenitor cells, 
which were equivalent to fetal 6- to 9-week pancreatic tis-
sue, and then transplanted into mice for further maturation. 
At 40 days after transplantation, the cells were stimulated 
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by glucose, and C-peptide release was detected in recipient 
mice, suggesting de novo synthesis of human insulin in 
mice. More importantly, these cells were able to correct 
STZ-induced hyperglycemia in mice. Using an appropriate 
induction protocol, these studies have shown that insu-
lin-secreting islet-like cells obtained in vitro and then trans-
planted in vivo may continue their maturation, and achieve 
the normal functions of  cells. Following the study of 
D’Amour, researchers began focusing more on improving 
the efficiency of ESC differentiation into pancreatic progen-
itor cells. Chen [25] found that the small molecule indolac-
tam V is capable of promoting the differentiation of human 
ESCs into PDX1-positive cells both in vitro and in vivo, 
which has provided a new method to obtain a large number 
of ESC-derived  cells.  
In addition to ESCs, iPSCs also provide hope for the 
treatment of diabetes. Bar-Nur [26] differentiated  cell-    
derived iPSCs into IPCs. These cells can secrete insulin 
upon stimulation by glucose and after transplantation into 
T2DM mice to normalize glycated hemoglobin levels and 
correct high blood glucose, thus providing evidence for the 
clinical application of iPSCs in T1DM/T2DM treatments. 
Currently, the most common strategy for iPSC induction 
involves genome-integrating viruses that carry an intrinsic 
risk of tumor formation because of the spontaneous reacti-
vation of viral transgenes. With the improvement of re-
search methods, the safety of iPSCs and their possible clin-
ical applications have been greatly enhanced. Stadtfeld [27] 
established a method to produce iPSCs using an adenovirus. 
In this method, exogenous genes are briefly and highly ex-
pressed within the cells, but not integrated into the genome, 
thus ensuring the safety of iPSCs in clinical application. 
Another method to produce iPSCs is the addition of appro-
priate growth factors to the culture medium of spermatogo-
nial stem cells for reprogramming to iPSCs that can differ-
entiate into cells of all three germ layers [28]. Because ex-
ogenous genes are not used in the conversion process, there 
is no exogenous gene integration or its related risks. In 2010, 
at the annual meeting of the American Society for Cell Bi-
ology, it was shown that spermatogonial stem cell-derived 
iPSCs can be induced to -like cells that react to physiolog-
ical levels of glucose in vitro and reduce the glucose levels 
of diabetic mice in vivo.  
Despite the encouraging results, these studies are still in 
the early stages of using ESCs and iPSCs in treatments for 
diabetes mellitus. The direct differentiation of pancreatic 
endocrine cells and the mechanism of functional islet matu-
ration remain unclear. Furthermore, another issue of con-
cern among the current studies is the lack of observation of 
the long-term efficacy and safety analyses of ESCs and  
iPSCs in treatments for diabetes, which signifies that a large 
amount of research must be performed before human clini-
cal trials can be conducted. 
1.3  Mesenchymal stem cells 
Bone marrow contains two different types of stem cells, 
namely hematopoietic stem cells (HSCs) and MSCs. Inves-
tigators successfully differentiated these two stem cell types 
into various types of cells, suggesting that they possess 
multipotency. Because bone marrow stem cells are easily 
obtained by clinical procedures, bone marrow cells have 
become one of the research focuses of cell therapy for dia-
betes [29]. 
At present, research focusing on the treatment of diabetes 
with bone marrow stem cells includes the following find-
ings [30]. Peripheral intravenous injection of MSCs can 
inhibit autoreactive T cells and alleviate the TIDM autoim-
mune reaction. Urban [31] showed that the immunomodu-
latory effect of MSCs is one of the mechanisms that assist  
cell regeneration. Investigators injected a mixture of HSCs 
and MSCs into the bone marrow of mice with STZ/radia-     
tion-induced injury, which successfully enabled the high 
blood glucose levels of the mice to return to normal. It is 
worth noting that the investigators found that MSCs were 
able to inhibit the proliferation of pancreatic  cell-specific 
T cells, thereby reducing the damage caused by T cells on 
new  cells and increasing  cell regeneration to a certain 
degree. Combined with islet transplantation, this method 
enables the implant to evade immune surveillance, and im-
proves the survival rate of the implant. Bone marrow MSCs 
have been shown to inhibit autoimmunization and alloim-
munization. Ding [32] took advantage of this feature to 
transplant bone marrow MSCs and allogeneic islets, a 
method that may prolong the survival time of the trans-
planted islets and maintain normal blood glucose for a sig-
nificant period of time. It was assumed that MSCs play a 
role in immune evasion and promote the survival of the 
transplanted islet by synthesis and secretion of matrix met-
alloproteinase 2 and 9 into the extracellular matrix. Bone 
marrow MSCs have also been differentiated into IPCs for 
cell replacement therapy. In early studies, researchers fo-
cused on the differentiation potential of bone marrow stem 
cells for their therapeutic effects. It was confirmed that bone 
marrow MSCs can differentiate into IPCs in vitro and in 
vivo, and correct high blood glucose levels in diabetic mice 
[33,34]. However, scientists questioned the ability of bone 
marrow MSCs to differentiate into IPCs because differenti-
ated bone marrow cells only account for a small portion of 
the transplanted cells [35]. It is also important to observe 
decreased levels of plasma glucose and increased levels of 
insulin before the presence of MSC derived IPCs. Therefore, 
the success of bone marrow MSCs in the treatment of dia-
betes is likely to be achieved by endocrine or paracrine 
mechanisms that assist the existing  cells, stimulate prolif-
eration and insulin secretion, and effectively control blood 
glucose levels, rather than by direct differentiation into β 
cells. 
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These in vivo studies elaborate on the potential of bone 
marrow stem cells to stimulate  cell regeneration in the 
injured pancreatic tissue, and various research perspectives 
have revealed different mechanisms of the effects of bone 
marrow stem cells. Although not all mechanisms can be 
elaborated in detail, bone marrow stem cells are able to 
stimulate the regeneration of damaged pancreatic -cells, 
or become an alternative  cell source after induction. 
There is no doubt that bone marrow stem cells have thera-
peutic effects on diabetes. Bone marrow stem cells are an 
ideal choice for future cell therapy and the treatment of di-
abetes.  
1.4  Hepatic stem cells 
In developmental biology, because the liver and pancreas 
originate from the endoderm and possess common progeni-
tor cells, it has been speculated that liver cells can be used 
as an alternative source of  cells [36]. Exogenous PDX1 
and NGN3 have been expressed in the mouse liver by ade-
noviral transduction, which in turn induced pancreatic en-
docrine and exocrine gene expression in liver cells. The 
transdifferentiated cells can survive in the liver for a long 
period of time. New pancreatic tissue clusters formed 
around the central veins of the liver, where they released 
insulin, but did not affect the normal liver function. More 
importantly, these insulin-secreting liver tissues corrected 
STZ-induced hyperglycemia to maintain normal blood glu-
cose levels for a period of 8 months [37,38]. However, 
Yang [39] found that, in some cases, PDX1-reprogrammed 
liver tissue is only capable of forming pancreatic  progen-
itor cells that only further differentiate into functional IPCs 
under a state of high glucose in vitro or in vivo. To date, no 
evidence has been found which shows that the modified 
liver cells proliferate in vitro and can reach a sufficient 
number of functional cells for transplantation therapy.  
Nevertheless, these liver tissues still have good prospects, 
and are not controversial like pancreatic stem cells. Because 
of its easy collection from biopsy and strong regenerative 
capacity, liver tissue has become an ideal source of seed 
cells for transdifferentiation. In the future, an effective 
method for in vitro expansion of cells transdifferentiated 
from liver will be required. The safety of transdifferentiated 
liver tissue induced in the human body also requires further 
exploration.  
2  Problems and prospects of cell therapy for 
diabetes mellitus 
Although the results of many studies have confirmed that 
stem cells can enable diabetic patients to maintain normal  
blood sugar levels independently from insulin administra-
tion for a period of several years, many problems exist for 
the application of stem cells in the clinical treatment of dia-
betes. The first of these challenges is the cell source. Each 
recipient requires approximately 100000 pancreatic islets 
for transplantation, and a large number of alternative cells 
must also be prepared in vitro. Despite the fact that several 
research teams have used various methods to differentiate 
stem cells into -like cells, when used in clinical application, 
these cells are far from meeting the functional requirements 
because of relatively low differentiation efficiency to the 
target cells. Therefore, based on further characterization of 
pancreatic islet development and differentiation, a relatively 
effective method for promoting the differentiation of stem 
cells into functional  cells should be developed, including 
large-scale production of transplantable cells. Second, there 
are numerous side effects associated with stem cell therapy, 
which cannot be ignored. Kroon [24] has shown that the 
probability of generating teratomas or other tissue compo-
nents exceeds 15% after transplantation of human ESC-     
derived pancreatic cells in mice. Other studies showed that 
in vitro proliferation of MSCs increases the risk of tumor 
formation and metastasis [40,41]. These safety issues must 
be carefully considered and evaluated before cell therapy 
can be used in clinical trials, and appropriate countermeas-
ures must be performed. In addition, there is the problem of 
immune rejection that is associated with stem cell therapy 
[42]. After receiving allogeneic cell therapy, patients must 
undergo immunosuppressive therapy. However, immuno-
suppressive drugs have a role in insulin resistance and inhi-
bition of insulin secretion, thus increasing the difficulty of 
implanting cells to maintain proper blood sugar levels. In 
addition, immunosuppressive drugs increase the risk of ma-
lignancy, although this effect is only found in kidney trans-
plantation. For the treatment of T1DM, after transplantation 
of alternative autologous cells, the cells will be quickly 
damaged by autoantibodies unless a method to protect such 
cells is found. For the treatment of T2DM, the cells will be 
scrutinized because the dysfunction of β cells is typically 
closely related to genetic abnormalities or changes. Trans-
plantation of -like cells from T2DM patients may not be 
able to control blood glucose levels for a significant amount 
of time. 
Any new treatment method for clinical applications will 
face many problems. Although these problems still remain, 
we have every reason to believe that islet cell replacement 
therapy and regenerative medicine will eventually be widely 
used in clinical practice, and that these methods will result 
in new clinical efficacy or possibly even a cure for diabetes, 
thus mitigating the suffering and reducing the social burden 
of diabetic patients. 
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Table 1  Summary of cell therapies for diabetes mellitusa) 
Type Source Induce strategies 
Transplantation site 
& cell number 
In vivo GRIR Advantages Limitations 
ES cells, e.g. 
CyT49,H8,H9 
[24,25] 
Inner cell mass 
Stepwise differentiation 





epididymal fat pads 
Yes Unlimited supply 
Risk of formation teratoma; 
ethical controversy 
iPS cells [26,43] 
Skin cells; pancre-




















Hepatic oval cell; 
biliary tree stem 






Autologous source; easy 
harvest; endodermal origin 
Difficulty achieving suffi-
cient in vitro cell mass for 







ductal cells and 
islet cells 













differentiation in vivo 
4.2×107 tail vein; 
2×106 renal capsular 
space and splenic vein 
Yes 
Easy harvest; promoting 
vascularization; induce 
regeneration of pancreatic 
IPC in pancreas; immuno-
protective 
Risk of malignant transfor-
mation in vitro; risk of tu-
mor development after 
transplantation; difficulty 
differentiation directly 
a) GRIR, glucose responsive insulin release; ES cells, embryonic stem cells; MSCs, mesenchymal stem cells; iPS cells, induced pluripotent stem cells.  
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